The U.S. FDA has issued two notices: seeking public comments on regulations regarding tobacco retailer training programs and sales restrictions

Aug.22.2025
The U.S. FDA has issued two notices: seeking public comments on regulations regarding tobacco retailer training programs and sales restrictions
On August 22, the U.S. FDA issued two notices soliciting public comments on regulations regarding tobacco retailer training programs and restrictions on tobacco sales. Both notices provide a 60-day public comment period under the Paperwork Reduction Act, aiming to protect public health, especially that of children and adolescents, by regulating retailer behavior and restricting tobacco sales.

Key points: 

·Tobacco retailer training program: The FDA plans to establish standards to regulate tobacco retailer training programs, covering topics such as federal laws restricting the sale, advertising, and promotion of tobacco products. It is estimated that approximately 239,100 tobacco retailers will need to develop training programs that conform to the guidelines. 

·Regulations on tobacco sales: These regulations aim to protect children and adolescents by restricting the sale and distribution of cigarettes and smokeless tobacco. Tobacco product manufacturers, distributors, and retailers are required to notify the FDA at least 30 days before using any advertising or labeling media not listed in the regulations. 

·Public comment period: Both notices provide a 60-day public comment period, during which the public can submit feedback electronically or in writing.

 


 

According to the FDA website's announcement on August 22nd, the U.S. FDA has issued two notifications in the Federal Register, one regarding tobacco retailer training programs and the other seeking public input on regulations limiting tobacco sales.

 

Tobacco Retailer Training Program (Docket No. FDA-2025-N-2653)

 

The FDA is considering establishing standards to regulate tobacco retailer training programs. These programs should cover federal laws regarding the sale, advertising, and promotion of tobacco products, the health and economic impacts of tobacco use, and policies prohibiting sales to minors. The FDA estimates that around 239,100 tobacco retailers will need to develop training programs that comply with these guidelines. The program will also include requirements such as written tests, annual training updates, and record-keeping. The FDA projects that the annual burden of developing training programs, establishing written policies, and conducting internal compliance checks for information collection activities will be 1,992,500 hours, with a record-keeping burden of 191,280 hours.

 

Regulations restricting tobacco sales (Docket No. FDA-2025-N-2652)

 

The regulation aims to protect children and adolescents by restricting the sale and distribution of both traditional and smokeless tobacco products. It requires tobacco product manufacturers, distributors, and retailers to notify the FDA at least 30 days before using any advertising or labeling medium not specifically listed in the regulation. The FDA anticipates approximately four respondents to submit alternative advertising notifications each year, with an average burden of 1 hour per notification. Since 2022, the FDA has received a total of 12 such notifications.

 

Public Opinion Consultation

 

Both notices are in accordance with the Paperwork Reduction Act of 1995, which requires a 60-day period for public comment. The public can submit electronic comments through the Federal eRulemaking Portal website, or submit written comments through mail, hand delivery, or courier. For comments containing confidential information, two copies must be submitted - one with the confidential information included, and the other with the confidential information removed for public viewing. The FDA will assess and adjust information collection activities based on public feedback.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Indonesia to Step Up Vape Surveillance as Concerns Rise Over Drug-Laced E-Cigarettes
Indonesia to Step Up Vape Surveillance as Concerns Rise Over Drug-Laced E-Cigarettes
Indonesia will strengthen surveillance of vapes amid growing concerns over drug-laced e-cigarettes. The National Food and Drug Monitoring Agency, or BPOM, will soon take charge of monitoring nationwide vape distribution and said it will work with the National Narcotics Agency, or BNN. BNN recently floated a plan to completely ban e-cigarettes, saying a total ban was the only way to prevent liquid narcotics.
May.11 by 2FIRSTS.ai
Japan Tobacco Q1 2026 Financial Results: Revenue at $5.914 Billion,RRP Revenue Up 63.8% YoY
Japan Tobacco Q1 2026 Financial Results: Revenue at $5.914 Billion,RRP Revenue Up 63.8% YoY
Japanese Tobacco (JT) reports Q1 2026 revenue of 924 billion yen, a 15.2% increase; operating profit rises 24.7%.
May.08 by 2FIRSTS.ai
Sweden Becomes First EU Country to Reach Smoke-Free Status as Daily Smoking Falls to 4.8%
Sweden Becomes First EU Country to Reach Smoke-Free Status as Daily Smoking Falls to 4.8%
According to the latest CAN report and multiple media reports, Sweden’s daily smoking rate fell to 4.8% in 2025, below the commonly used 5% smoke-free threshold, making it the first EU country to reach that benchmark.
News
Jun.05
Ukrainian Media: Polish Vape Distributor Evapify Allegedly Linked to Russian Businessman Named in U.S. “Russia Oligarch Report”
Ukrainian Media: Polish Vape Distributor Evapify Allegedly Linked to Russian Businessman Named in U.S. “Russia Oligarch Report”
According to an investigative report by Euromaidan Press, a Ukrainian English-language independent media outlet, Russian businessman Oleg Boyko has been sanctioned by Ukraine, Poland, Australia and Canada, but has not been added to the European Union’s sanctions list. The report alleges that Evapify, a Polish vape distributor with financial and personal ties to Boyko, holds a significant position in Poland’s disposable vape market.
News
Jun.01
Malaysia Police Plan Saliva Tests at Roadblocks to Detect Synthetic Drugs Mixed Into Vape Liquids
Malaysia Police Plan Saliva Tests at Roadblocks to Detect Synthetic Drugs Mixed Into Vape Liquids
Malaysian police plan to use saliva test kits at roadblocks to detect drivers using synthetic liquid drugs marketed as “Piu Piu” and “Magic Mushroom,” substances that authorities say are mixed into vape liquids and inhaled through e-cigarette devices, raising road-safety concerns and adding pressure on vape regulation.
Jun.29
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Ispire and Jincheng Pharma Form Joint Venture to Enter Global High-Growth Nicotine Pouch Market
Summary Ispire Technology announced a strategic joint venture with Chinese pharmaceutical company Jincheng Pharma to manufacture and commercialize nicotine pouch products. The partnership combines pharmaceutical-grade production capabilities with Ispire’s global regulatory infrastructure and distribution network as the company expands beyond vaping hardware into oral nicotine products.
Business
May.13